, it is also possible that we simply do not know what to look for in humans.
Sorrells et al. minimized these issues in several ways. First, they observed neurogenesis in the hippocampus of infants and children, which served as a positive control. Second, they used a variety of adult samples to mini mize the possibility that problems with tissue health or preservation could confound their results. Third, they used diverse markers of neurogenesis to gain multiple lines of evidence. Nonetheless, further investigation will be needed to see whether Sorrells and colleagues' conclusions will stand the test of time.
How do the authors' findings fit with the animal literature? With a bit of conceptual recalibration, they might fit quite well. Rodents are born with relatively immature nervous sys tems, so adult rodent neurogenesis could be a decent model of neurogenesis in children or adolescents. Given that depression, schizo phrenia and Alzheimer's disease are rooted in early hippocampal defects, even neurons generated in childhood could have a key role in the aetiology of disease in humans. In addi tion, primate data 10 suggest that new neurons in humans could go through an extended period of maturation (years or even decades)
P R AT I T I B A N D O PA D H AYAY & M AT T H E W M E Y E R S O N
T he mapping of the human genome, followed by the explosion in next generation genome sequencing, has revolutionized our understanding of cancer. These advances have paved the way for pre cisionmedicine approaches to treating adult cancers. Two papers in Nature report the first pancancer genomic analyses in children. In the first, Gröbner et al. 1 (page 321) analysed sequences of whole exomes (all the protein coding regions in the genome) or whole genomes for 961 cancers across 24 tumour types, with an emphasis on tumours of the central nervous system. In the second, Ma et al. 2 (page 371) used similar analyses to characterize 1,699 cancers across 6 types of cancer tissue, particularly leukaemias.
CANCER GENOMICS

Landscapes of childhood tumours
Two analyses of the genetic alterations that characterize paediatric cancers reveal key differences from adult cancers, and point to ways of optimizing therapeutic approaches to combating cancer in children. See Article p.321 & Letter p.371 relative to what occurs in rodents, during which time they might have enhanced plastic ity and important functional properties. Thus, whereas the continual addition of new neurons might provide plasticity in adult rodents, the prolonged development of neurons could pro vide a similar plasticity in adult humans.
At the other end of the developmental spectrum, even in rodents, neurogenesis is very low by middle age 2 . Thus, Sorrells and colleagues' human data again are not wholly inconsistent with the animal literature. If the focus of rodent studies were shifted to identifying the mechanisms by which neuro genesis diminishes over time, and to how neurogenesis can be enhanced to offset pathol ogy caused by age and disease, we just might be able to translate the authors' sobering findings into discoveries that improve human health. ■ The findings provide valuable insights into the mechanisms that shape the genomes of childhood cancers.
Jason S. Snyder is in the Department
Adult cancers frequently involve multiple genetic alterations that together drive cancer progression, including small mutations of one or a few DNA bases, and larger changes called structural variants that span more than 1,000 bases. Such drivers can be shared across cancer types 3 . One of the most meaningful out comes of the current studies is their confirma tion that the genomic landscape of childhood cancers differs from this picture. Previous studies of individual paediatric cancer types [4] [5] [6] [7] have revealed that they have fewer mutations and structural variants, on average, than do adult cancers 3, 8 , but the current pancancer analyses take this further, systematically highlighting several key differences between childhood and adult cancer genomes (see 'The differing genomic landscapes of childhood and adult cancers').
First, there are fewer mutations and structural variants in paediatric cancers than in adult cancers. For instance, Gröbner et al. report a mutation rate 14 times lower for child hood than for adult cancers. Furthermore, both groups find that the total number of mutations in paediatriccancer genomes correlates signifi cantly with age -consistent with the idea that cells accumulate mutations with age.
Second, paediatric cancers are frequently defined by a single driver gene. For instance, 57% of the cancers in Gröbner and colleagues' analysis harboured single driver mutations. These authors also highlight the fact that germ line mutations, which are inherited from parents and are present in all cells of the body, are a causative factor in childhood cancers -7.6% of cancers in the authors' cohort are associated with detectable germline muta tions. Furthermore, paediatric cancers tend to be enriched in either mutations or structural variants, rather than a mixture of the two. Indeed, the group observes enrichment of germline mutations involved in a DNArepair pathway called mismatch repair in cancers defined by mutations, and germline mutations in a tumoursuppressor gene, TP53, in cancers characterized by structural variants. These differences highlight potential mechanisms by which different paediatric cancer genomes are shaped.
Third, different genes are mutated in paediatric compared with adult cancers. Only 30% of significantly mutated genes identified by Gröbner and coworkers (those that have acquired more mutations than would have been expected to occur by chance, and so are likely to be involved in cancer progression), and only 45% of those reported by Ma and colleagues, over lap with adult pancancer analyses. These differences are borne out in the groups' mutationsignature analyses, which provide information about the mutational processes that lead to a particular pattern of mutations.
Fourth, and perhaps most intriguingly, driver mutations tend to be specific to individual paediatric cancer types, with minimal over lap across diseases. This is in contrast to adult cancers, which more frequently share mutations across types, according to Gröbner and colleagues' analysis. This finding by the current studies might reflect the differing paths to cancer development between adult and paediatric cancers. Adult cancers often arise through a multiplehit process in which alterations in genes generally beneficial to cell survival accumulate as cells become cancer ous 9 . By contrast, a model of paediatric cancers posits that, in some cases, a single, specific driver alteration might promote cancer devel opment in certain cell lineages, if it results in aberrant gene expres sion during a crucial period of develop ment 6 . Indeed, a study in mice has also highlighted the importance of develop mental con text and the timing of genomic perturbation in tumour development 10 . The insights gleaned from the current analyses have implications for precision medicine approaches for childhood cancers. Gröbner et al. found that about 50% of the tumours that they profiled harbour genomic alterations that can be targeted (directly or indirectly) by drugs that are available or under development. This number, which is consist ent with previous reports 11, 12 , is a cause for optimism. The findings also provide insights into how clinical assays could be designed to ensure robust detection of alterations specific to paediatric tumours. Assays must profile genes that are significantly mutated across childhood cancers, with sufficient sensitiv ity to detect single driver alterations in an individual's genome, and must be specifically designed to include mutations and struc tural variants in both coding and noncoding regions of the genome.
Furthermore, the studies reinforce the need for paediatric oncologists to consider the high incidence of germline mutations in their patients. Clinicians should offer genetic coun selling (in which patients are advised about risks and management options for genetic disorders), testing for germline alterations and appropriate screening for families who are found to harbour germline mutations.
Although the current studies provide valuable insights, much work is still required to complete the picture. Gröbner and colleagues were unable to identify driver alter ations in 10% of tumours, and neither group analysed enough samples in a specific cancer type to detect infrequent mutations. Child hood cancers are, by definition, rare tumours. Continued collaboration and datasharing are required to amass information from enough tumours of each type to comprehensively identify recurrent driver alterations. Fur thermore, given that both groups identified structural variants, which often occur in non coding regions, wholegenome sequencing is needed to detect drivers outside coding regions. Data from both studies are avail able for review -Gröbner and colleagues' at go.nature.com/2bq3oyh, and Ma and col leagues' at go.nature.com/2svr9hh. This is a key step in paving the way for further analytical efforts across large cohorts of paediatric tumours.
Last but not least, it will be necessary to elucidate the mechanisms by which the identified genetic alterations drive childhood cancer. This will improve our ability to target these alterations therapeutically. ■
